Table 1 Baseline characteristics
From: Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
Patient Characteristics | Total (N = 50) |
|---|---|
Age, median(range) | 54(38–72) |
Prior chemotherapy lines, No.(%) | |
0 | 24(48%) |
1 | 6(12%) |
≥ 2 | 20(40%) |
Optimal therapeutic effect, NO(%) | |
PD | 10(20%) |
SD | 26(52%) |
PR | 11(22%) |
CR | 3(6%) |
HER-2 expression.NO(%) | |
0 | 30(60%) |
1+/2+ | 20(40%) |
Hepatic metastases.NO(%) | |
Yes | 12(24%) |
No | 36(76% |
Brain metastases.NO(%) | |
Yes | 7(14%) |
No | 43(86%) |
Lung metastasis.NO(%) | |
Yes | 28(56%) |
No | 22(44%) |
Chest wall metastasis.NO(%) | |
Yes | 24(48%) |
No | 26(52%) |
Bone metastases.NO(%) | |
Yes | 23(46%) |
No | 27(54%) |
Immune adverse effects.NO(%) | |
Yes | 13(26%) |
No | 37(74%) |